At the time of FDA approval for Invokana (canagliflozin) in 2013, the benefits versus risks of the prescription medication to treat diabetes had already become highly questionable. Within the first two years of availability in the United States, serious concerns over the drug turned to reality when clinical studies showed users were experiencing reduced bone density in their hips and lower spine.
Invokana is a glifozin class drug that is prescribed by family doctors to treat Type II diabetes. Developed and manufactured by Mitsubishi Tanabe Pharma, the prescription medication is marketed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. The oral diabetes prescription medication has shown to be highly effective in controlling blood sugar levels by assisting the kidneys in ridding the body of glucose in the bloodstream. The drug marketers claim that with exercise and diet, Invokana can be highly effective at treating and controlling diabetes.
Even before the prescription medication had become available in the United States, the pharmaceutical manufacturer and marketers had already become aware that the drug posed serious problems, even during short-term use. Before its approval in the U.S., many patients in other countries that already suffered serious kidney damage or become victims of heart attacks and ketoacidosis. In some cases, patients were suffering bone fractures in less than 90 days after first taking the drug. The risk of fractures and bone loss seem to be most prominent in women of post-menopausal age.
The FDA Warning
In October 2015, the FDA (Food and Drug Administration) issued a warning advising doctors to consider the high potential risks of bone fractures before prescribing Invokana or generic canagliflozin medications. The FDA is also monitoring similar glifozin drugs that are all SLGT2 (sodium-glucose co-transporter-2) inhibitors. These drugs are designed to lower blood sugar levels by blocking glucose reabsorption in the kidneys. It does this through an increased excretion in urine.
Long before the FDA warning, Mitsubishi Tanabe Pharma and Janssen Pharmaceuticals had begun saturating the market of family doctors with materials promoting Invokana as a wonderful effective drug. However, during this time, experts reviewing the medication showed ambivalence because clinical studies indicated a high risk to patients already suffering with cardiovascular disease, noting that the medication seem to increase heart attack levels.
Opponents of the drug becoming legal in the United States show that the medicine label did not include a warning concerning strokes and heart attacks. As a result, even the most conscientious family doctor would have little to no idea of the exposure to adverse side effects when prescribing the medication to their patients suffering Type II diabetes. In addition, these opponents also showed concerns that the medication has been proven highly dangerous for individuals suffering kidney disease.
Study findings published in Diabetes Care, a well-respected medical journal show that Invokana was helpful for individuals Type I diabetic requiring glycemic control. However, the study showed that the drug also increases potential risk of developing ketoacidosis, or high acid levels in the bloodstream cause significant health complications that often require emergent hospital treatment.
Hiring an Invokana Injury Attorney
As of yet, claims for compensation against the manufacturer and marketer of Invokana have not reached the status of a class action suit. Currently, reputable personal injury attorneys including Rosenfeld Injury Lawyers are filing individual lawsuits and claims for compensation on behalf of their clients. To raise concerns about the development of osteoporosis as a direct result of taking Invokana, other claim for compensation involve:
- Kidney failure and impairment,
- Developing kidney stones associated with Invokana use,
- Fluid imbalance and severe dehydration,
- Abnormal weight loss,
- Urinary tract infections caused by the diabetic drug.
The bad drug injury attorneys at Rosenfeld Injury Lawyers can provide you with various legal options to hold Mitsubishi Tanabe Pharma and Janssen Pharmaceuticals financially accountable for your damages, losses and injuries. Our team of skilled, experienced attorneys can help build a case for compensation by showing the marketer and manufacturer’s failure to warn you of potential risk, negligence making and selling a defective medication and misrepresenting the benefits and risks of Invokana. We encourage you to call our law offices today at (888) 424-5757 to discuss your claim for compensation.